AC
NKGN

Aristeia Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Aristeia Capital’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-806,666
Closed -$8.17M – 299
2023
Q1 		$8.17M Buy
+806,666
New +$8.14M 0.19% 118

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Aristeia Capital's NKGN Position: Q2 2023 in Review

Aristeia Capital sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 806,666 shares — an estimated $8.17M sold.

Aristeia Capital first reported a position in NKGN in Q1 2023 and held it in 1 quarter. The position peaked at $8.17M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Aristeia Capital reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Aristeia Capital sold 806,666 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $8.17M.
  • Aristeia Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Aristeia Capital's NKGen Biotech, Inc. Common Stock position peaked at $8.17M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Aristeia Capital's 13F filing for Q2 2023, filed 14 Aug 2023.